Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 4/20 | 0.44 |
| ▸ | GABRR1 | P24046 | 3/20 | 0.44 |
| ▸ | GABRR2 | P28476 | 2/20 | 0.44 |
| ▸ | BLM | P54132 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.44 |
| ▸ | APEX1 | P27695 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA7 | P43166 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.42 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.42 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8118802 | 1.00 | HCAR2 (0.54) | HCAR2LMNAGABRR1GABRR2BLM | |
| SCHEMBL317284 | 0.80 | GABRR1 (0.39) | HCAR2LMNAGABRR1GABRR2BLM | |
| SCHEMBL691429 | 0.80 | HCAR2 (0.56) | HCAR2LMNATSHRTDP1CA12 | |
| SCHEMBL28414984 | 0.80 | HCAR2 (0.56) | HCAR2LMNATSHRTDP1CA12 | |
| SCHEMBL27110712 | 0.80 | HCAR2 (0.56) | HCAR2LMNATSHRTDP1CA12 | |
| SCHEMBL691430 | 0.80 | HCAR2 (0.56) | HCAR2LMNATSHRTDP1CA12 | |
| SCHEMBL27731569 | 0.78 | HCAR2 (0.54) | HCAR2LMNATSHRTDP1CA12 | |
| SCHEMBL177748 | 0.78 | HCAR2 (0.80) | HCAR2LMNATSHRTDP1CA12 | |
| SCHEMBL177747 | 0.78 | HCAR2 (0.80) | HCAR2LMNATSHRTDP1CA12 | |
| SCHEMBL178194 | 0.78 | HCAR2 (0.80) | HCAR2LMNATSHRTDP1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0657430-B1 | Isopropyl-(2-methoxyethyl)-4-(2-chloro-3-cyano-phenyl)-1,4-dihydro-2,6-dimethyl-piridine-3,5-dicarboxylate | BAYER AG (DE) | 1999-06-02 | — | — | EP | claimed |
| US-5665740-A | Isopropyl 2-methoxyethyl 4-(2-chloro-3-cyano-phenyl)-1, 4-dihydro-2,6-dimethyl-pyridine-3,5-dica rboxylate | BAYER AKTIENGESELLSCHAFT (DE) | 1997-09-09 | — | — | US | claimed |
| EP-0657430-A1 | Isopropyl-(2-methoxyethyl)-4-(2-chloro-3-cyano-phenyl)-1,4-dihydro-2,6-dimethyl-piridine-3,5-dicarboxylate | BAYER AG (DE) | 1995-06-14 | — | — | EP | claimed |
| US-20090156639-A1 | COMPOSITIONS AND METHODS OF TREATMENT USING L-TYPE CALCIUM CHANNEL BLOCKERS AND CHOLINESTERASE INHIBITORS | TRIPPODI-MURPHY CRISTA | 2009-06-18 | — | — | US | disclosed |
| US-20090069361-A1 | METHODS OF TREATMENT USING (+)- ISOPROPYL 2-METHOXYETHYL 4-(2-CHLORO-3-CYANO-PHENYL)-1, 4-DIHYDRO-2, 6-DIMETHYL-PYRIDINE-3, 5-DICARBOXYLATE | MEMORY PHARMACEUTICALS CORPORATION (US) | 2009-03-12 | — | — | US | disclosed |
| EP-1952824-A1 | Compositions and methods of treatment using L-type calcium channel blockers and cholinesterase inhibitors | Memory Pharmaceuticals Corporation (US) | 2008-08-06 | — | — | EP | disclosed |
| EP-1684806-B1 | COMPOSITIONS COMPRISING L-TYPE CALCIUM CHANNEL BLOCKERS AND CHOLINESTERASE INHIBITORS | MEMORY PHARM CORP (US) | 2008-06-25 | — | — | EP | disclosed |
| US-20080026081-A1 | Methods of Treatment Using (+)-Isopropyl 2-Ethoxyethyl-4-(2-Chloro-3-Cyano-Phenyl)-1,4-Dihydro-2,6-Dimethyl-Pyridine-3,5-Dicarboxylate | MEMORY PHARMACEUTICALS CORPORATION | 2008-01-31 | — | — | US | disclosed |
| EP-1684755-A1 | USE OF (+)-ISOPROPYL 2-METHOXYETHYL 4-(2-CHLORO-3-CYANO-PHENYL)-1,4-DIHYDRO-2,6-DYMETHYL-PYRIDINE-3,5-DICARBOXYLATE IN THE TREATMENT OF MEMORY DISORDERS | Memory Pharmaceutical Corporation (US) | 2006-08-02 | — | — | EP | disclosed |
| EP-1684806-A1 | COMPOSITIONS AND METHODS OF TREATMENT USING L-TYPE CALCIUM CHANNEL BLOCKERS AND CHOLINESTERASE INHIBITORS | Memory Pharmaceutical Corporation (US) | 2006-08-02 | — | — | EP | disclosed |
| US-20050153953-A1 | Compositions and methods of treatment using L-type calcium channel blockers and cholinesterase inhibitors | MEMORY PHARMACEUTICAL | 2005-07-14 | — | — | US | disclosed |
| WO-2005051426-A1 | COMPOSITIONS AND METHODS OF TREATMENT USING L-TYPE CALCIUM CHANNEL BLOCKERS AND CHOLINESTERASE INHIBITORS | MEMORY PHARMACEUTICAL CORPORATION (US) | 2005-06-09 | — | — | WO | disclosed |
| WO-2005051389-A1 | USING OF (+)-ISOPROPYL 2-METHOXYETHYL 4-(2-CHLORO-3-CYANO-PHENYL)-1,4-DIHYDRO-2,6-DYMETHYL-PYRIDINE-3,5-DICARBOXYLATE IN THE TREATMENT OF MEMORY DISORDERS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2005-06-09 | — | — | WO | disclosed |
| EP-0657430-B1 | Isopropyl-(2-methoxyethyl)-4-(2-chloro-3-cyano-phenyl)-1,4-dihydro-2,6-dimethyl-piridine-3,5-dicarboxylate | BAYER AG (DE) | 1999-06-02 | — | — | EP | disclosed |
| US-5665740-A | Isopropyl 2-methoxyethyl 4-(2-chloro-3-cyano-phenyl)-1, 4-dihydro-2,6-dimethyl-pyridine-3,5-dica rboxylate | BAYER AKTIENGESELLSCHAFT (DE) | 1997-09-09 | — | — | US | disclosed |
| EP-0657430-A1 | Isopropyl-(2-methoxyethyl)-4-(2-chloro-3-cyano-phenyl)-1,4-dihydro-2,6-dimethyl-piridine-3,5-dicarboxylate | BAYER AG (DE) | 1995-06-14 | — | — | EP | disclosed |